1 Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
2 National Heart and Lung Institute, Imperial College London, London, UK.
Chron Respir Dis. 2018 Feb;15(1):60-70. doi: 10.1177/1479972317702140. Epub 2017 Apr 10.
Asthma has been associated with a higher incidence of myocardial infarction (MI), higher prevalence of MI risk factors and higher burden of cardiovascular diseases. However, detailed associations between the presentation and initial management at the time of MI and post-MI outcomes in people with asthma compared to the general population have not been studied. A total of 300,161 people were identified with a first MI over the period 2003-2013 in the Myocardial Ischaemia National Audit Project database, of whom 8922 (3%) had asthma. Logistic regression was used to compare presentation, in-hospital care, in-hospital and 180-day post-discharge all-cause mortality in people with and without asthma adjusting for demographics and comorbidities, diagnosis on arrival and secondary prevention. People with asthma were more likely to have a delay in their MI diagnosis following an STEMI (ST-elevation myocardial infarction; odds ratio (OR) 1.38, confidence interval CI 1.06-1.79) but not an nSTEMI (non-ST-elevation myocardial infarction; OR 1.04, CI 0.92-1.17) compared to people without asthma and a delay in reperfusion (OR 1.19, CI 1.09-1.30) following an STEMI. They were much less likely to be discharged on a beta blocker following an STEMI or nSTEMI (OR 0.24, CI 0.21-0.28 and OR 0.27, CI 0.24-0.30, respectively). There was no difference in in-hospital or 180-day mortality (OR 0.98, CI 0.59-1.62 and OR 0.99, CI 0.72-1.36) following an STEMI or nSTEMI (OR 0.89, CI 0.47-1.68 and OR 1.05, CI 0.85-1.28). Although people with asthma were more likely to have a delay in diagnosis following an STEMI but not an nSTEMI compared to the general population, were more likely to have a delay in reperfusion therapy and were much less likely to receive beta blockers following an STEMI or nSTEMI, there was no difference in the prescriptions of other secondary prevention medications. None of the differences in presentation or management were associated with an increase in all-cause in-hospital or 180-day mortality in people with asthma compared to the general population.
哮喘与心肌梗死(MI)发生率较高、MI 风险因素患病率较高和心血管疾病负担较高有关。然而,与一般人群相比,哮喘患者在 MI 时的表现和初始管理以及 MI 后结局之间的详细关联尚未得到研究。在心肌缺血国家审计项目数据库中,2003 年至 2013 年间共确定了 300161 例首次 MI 患者,其中 8922 例(3%)患有哮喘。使用逻辑回归比较了有和没有哮喘的患者在 MI 时的表现、住院期间的护理、住院期间和出院后 180 天的全因死亡率,调整了人口统计学因素和合并症、入院时的诊断以及二级预防。与没有哮喘的患者相比,哮喘患者在 STEMI(ST 段抬高型心肌梗死)后 MI 诊断延迟(优势比[OR]1.38,95%置信区间[CI]1.06-1.79),但在 nSTEMI(非 ST 段抬高型心肌梗死)后没有延迟(OR 1.04,CI 0.92-1.17),STEMI 后再灌注延迟(OR 1.19,CI 1.09-1.30)。与 STEMI 或 nSTEMI 后相比,他们更不可能在 STEMI 或 nSTEMI 后出院时使用β受体阻滞剂(OR 0.24,CI 0.21-0.28 和 OR 0.27,CI 0.24-0.30)。STEMI 或 nSTEMI 后住院期间或 180 天死亡率无差异(OR 0.98,CI 0.59-1.62 和 OR 0.99,CI 0.72-1.36)(OR 0.89,CI 0.47-1.68 和 OR 1.05,CI 0.85-1.28)。尽管与一般人群相比,哮喘患者在 STEMI 后更有可能出现延迟诊断,但在 nSTEMI 后则没有,他们更有可能出现再灌注治疗延迟,并且在 STEMI 或 nSTEMI 后使用β受体阻滞剂的可能性更小,但其他二级预防药物的处方则没有差异。与一般人群相比,哮喘患者在表现和治疗管理方面的差异均与住院或 180 天全因死亡率的增加无关。